ArticleJournal of managed care & specialty pharmacy2026
Assessing the impact of pharmacist-led interventions on glucagon-like peptide 1 receptor agonist access and treatment outcomes.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Disparities in GLP-1RA and SGLT2i Uptake: a Systematic Review and an Equity-First Framework for Cardiovascular-Kidney-Metabolic Care.Current cardiology reports · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained popularity because of their demonstrated efficacy in weight loss, resulting in access barriers such as delays due to prior authorizations (PAs), insurance coverage restrictions, and limited availability. The national average for PA turnaround times is currently 72 hours. To offer solutions to these barriers, the University of Colorado Hospital (UCHealth) has integrated a pharmacy team into their primary care practice setting to provide specialized support to enhance access.
objectiveTo evaluate how pharmacist-led interventions affected PA turnaround times for GLP-1 RAs prescribed for weight loss. Additionally, we aimed to characterize these interventions to better understand the pharmacist's role in integrated care teams for weight management.
methodsThis retrospective cohort study used UCHealth electronic health records to evaluate pharmacist-led interventions identified by multistep order transmittal workflow in September 2024. The primary endpoint was PA turnaround time. The secondary endpoints included time to GLP-1 RA initiation, qualitative assessments of pharmacist-led interventions, and dosing optimizations. Survival analyses and descriptive analyses were conducted for time-to-event and qualitative endpoints.
resultsA total of 142 patients were included in this study. Fifty-six patients were observed in the PA-approved group and 86 patients in the PA-denied group. The median turnaround time for any PA decision was 19.87 hours (95% CI = 6.88-23.58). PA approvals had a median turnaround time of 47.1 hours (95% CI = 23.4-69.6), whereas PA denials had 3.6 hours (95% CI = 2.4-16.7) (
conclusionsIntegrating pharmacists into care teams can enhance GLP-1 RA PA turnaround times while improving medication access, safety, and continuity of care. These findings support further research and policy development in pharmacist interventions in PA process and GLP-1 RA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.